MERTK INHIBITOR-ASSOCIATED RETINAL TOXICITY IN A HUMAN
Patients taking MERTK inhibitors should be monitored by an ophthalmologist while on the drug. If toxicity develops, discussion of whether to continue the medication should take place between the patient, ophthalmologist, and oncologist, with consideration of the risks of vision loss versus benefits of taking the medication from a cancer perspective.
Authors
- Anne Strong Caldwell (ORCID: https://orcid.org/0000-0001-6017-8722)
- Dallin Milner
- Zafar S. Gill
- Niranjan Manoharan (ORCID: https://orcid.org/0000-0001-5746-6854)
- Nihaal Mehta
- Alejandro I Marin
Institutions
- University of Colorado Denver (US)
Publication Details
- Journal
- Retinal Cases & Brief Reports
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1097/icb.0000000000001654
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00